Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies

Clicks: 155
ID: 268121
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #438 of 1,084 articles by views in clinical infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,084 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Protease inhibitor (PI) monotherapy is a potential approach to alleviate antiretroviral treatment. We pooled the results of 3 PI/r monotherapy trials and demons
Reference Key
sidonie2018clinicalultrasensitive Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lambert-Niclot, Sidonie;Grude, Maxime;Meynard, Jean-Luc;Marcelin, Anne-Geneviève;Valantin, Marc-Antoine;Flandre, Philippe;Izopet, Jacques;Moinot, Laetitia;Bouteloup, Vincent;Calvez, Vincent;Katlama, Christine;Girard, Pierre-Marie;Morand-Joubert, Laurence;
Journal clinical infectious diseases
Year 2018
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.